Press Releases Viking Therapeutics, Inc.

Equities

VKTX

US92686J1060

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-14 EDT			5-day change	1st Jan Change
72.5 ^USD	+0.21%		-8.93%	+289.58%

05-06	Viking Therapeutics Insider Sold Shares Worth $4,986,008, According to a Recent SEC Filing	MT
05-03	Wall St set to open sharply higher on soft jobs data	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

6 Stocks Positioned to Soar as Investors Focus on MASH	04-22	AQ
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024	04-17	PR
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735	03-26	PR
Viking Therapeutics Announces $632.5 Million Public Offering Of Common Stock	03-13	AQ
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares	03-04	PR
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock	02-28	PR
Viking Therapeutics Announces Proposed Public Offering of Common Stock	02-27	PR
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity	02-27	PR
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024	01-31	PR
Viking Therapeutics to Participate at Upcoming Investor Conferences	11-02	PR
Adrenoleukodystrophy Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	23-10-27	AQ
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	23-10-26	AQ
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity	23-10-23	PR
Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023	23-10-18	PR
Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023	23-10-17	PR
Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023	23-10-10	PR
Viking Therapeutics to Participate at Upcoming Investor Conferences	23-09-07	PR
Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity	23-09-06	PR
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update	23-07-26	PR
Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023	23-07-19	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Viking Therapeutics, Inc.

Equities

VKTX

US92686J1060

Press Releases

Filters